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2007-2008 Influenza Season 
Week 6, ending February 9, 2008 
 (All data are preliminary and may change as more reports are received.) 
Synopsis:  During week 6 (February 3 - 9, 2008), influenza activity continued to increase in the 
United States.   
o Two thousand one hundred twenty-six (33.3%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza was above the epidemic 
threshold for the fifth consecutive week. 
o The proportion of outpatient visits for influenza-like illness (ILI) and acute respiratory illness 
(ARI) was above national baseline levels. ILI increased in eight of the nine regions 
compared to week 5, and was above region-specific baselines in all nine regions.  The East 
North Central, East South Central, Mountain, Pacific, West North Central, and West South 
Central regions reported ARI above their region specific baselines.   
o Forty-four states reported widespread influenza activity; five states reported regional 
influenza activity; one state and the District of Columbia reported local influenza activity; and 
Puerto Rico reported sporadic influenza activity. 
National and Regional Summary of Select Surveillance Components 
  Data for current week Data cumulative for the season 
  
Sentinel 
Provider 
ILI* 
DoD and 
VA ARI* 
% pos. 
for flu†
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity‡  
A 
(H1) 
A 
(H3) 
A 
Unsub-
typed 
B Pediatric Deaths 
Nation Elevated Elevated 33.3% 49 of 51  1033 1266 6590 1679 10 
New 
England Elevated Normal 15.2% 6 of 6 29 12 183 144 0 
Mid-
Atlantic Elevated Normal 19.2% 3 of 3 56 16 280 338 2 
East North 
Central Elevated Elevated 47.6% 5 of 5 90 294 249 143 0 
West 
North 
Central Elevated Elevated 24.5% 7 of 7 38 31 652 104 0 
South 
Atlantic Elevated Normal 28.2% 7 of 9 137 450 1523 295 0 
East 
South 
Central Elevated Elevated 25.0% 4 of 4 8 87 22 9 3 
West South 
Central Elevated Elevated 34.8% 4 of 4 54 196 2925 291 4 
Mountain Elevated Elevated 24.7% 8 of 8 303 132 404 221 0 
Pacific Elevated Elevated 17.9% 5 of 5 318 48 352 134 1 
 
* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline 
† National data are for current week; regional data are for the most recent three weeks. 
‡ Includes all 50 states and the District of Columbia 
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Laboratory Surveillance:  During week 6, WHO and NREVSS laboratories reported 6,382 
specimens tested for influenza viruses, 2,126 (33.3%) of which were positive, including 70 influenza 
A (H1) viruses, 322 influenza A (H3) viruses, 1,356 influenza A viruses that were not subtyped, and 
378 influenza B viruses.  The District of Columbia and 47 states from all nine surveillance regions 
have reported laboratory-confirmed influenza this season. 
 
Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 94,502 
specimens for influenza viruses and 10,568 (11.2%) were positive. Among the 10,568 influenza 
viruses, 8,889 (84.1%) were influenza A viruses and 1,679 (15.9%) were influenza B viruses.  Two 
thousand two hundred ninety-nine (25.9%) of the 8,889 influenza A viruses have been subtyped: 
1,033 (44.9%) were influenza A (H1) viruses and 1,266 (55.1%) were influenza A (H3) viruses. 
 
Although influenza A (H1) viruses predominated through mid-January, an increasing proportion of 
subtyped influenza A viruses are influenza A (H3) viruses. Influenza A (H3) viruses were reported 
more frequently than influenza A (H1) viruses during January 20–February 9.  During week 6, 
influenza A (H3) became the predominant virus for the season overall.  This season influenza A 
(H3) viruses have been reported more frequently than A (H1) viruses nationally, as well as in four of 
the nine surveillance regions (East North Central, East South Central, South Atlantic, and West 
South Central). 
 
U.S. WHO/NREVSS Collaborating Laboratories
National Summary, 2007-08
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Antigenic Characterization:  CDC has antigenically characterized 250 influenza viruses [117 
influenza A (H1N1), 65 influenza A (H3N2), and 68 influenza B viruses] collected by U.S. 
laboratories since September 30, 2007. 
 
Influenza A (H1N1) [117] 
• One hundred seven (91%) of the 117 viruses were characterized as A/Solomon 
Islands/3/2006, the influenza A (H1N1) component of the 2007-08 influenza vaccine 
for the Northern Hemisphere and the 2008 influenza A (H1N1) component for the 
Southern Hemisphere. 
• Ten (9%) of the 117 viruses showed somewhat reduced titers with antisera produced 
against A/Solomon Islands/3/2006. 
 
Influenza A (H3N2) [65] 
• Nine (14%) of the 65 viruses were characterized as A/Wisconsin/67/2005-like, the 
influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern 
Hemisphere. 
• Fifty-three (81%) of the 65 viruses were characterized as A/Brisbane/10/2007-like.  
A/Brisbane/10/2007 is a recent antigenic variant which evolved from 
A/Wisconsin/67/2005-like.  A/Brisbane/10/2007-like virus is the recommended 
influenza A (H3N2) component for the 2008 Southern Hemisphere vaccine. 
• Three (5%) of the 65 viruses showed somewhat reduced titers with antisera 
produced against A/Wisconsin/67/2005 and A/Brisbane/10/2007. 
 
 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [68] 
  
Victoria lineage [4] 
• Four (6%) of the 68 influenza B viruses characterized belong to the B/Victoria 
lineage of viruses. 
o Two (50%) of these 4 viruses were characterized as B/Ohio/01/2005-like. The 
recommended influenza B component for the 2007-08 influenza vaccine is a 
B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage.  
B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain. 
o Two (50%) of these 4 viruses showed somewhat reduced titers with antisera 
produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.  
 
Yamagata lineage [64] 
• Sixty-four (94%) of the 68 viruses were identified as belonging to the B/Yamagata 
lineage of viruses. 
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Antiviral Resistance: In the United States, two groups of antiviral drugs have been approved by 
FDA for use in treating or preventing influenza infections.  These two groups of antiviral drugs are: 
neuraminidase inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and 
rimantidine). A description of these drugs can be found at: 
http://www.cdc.gov/flu/protect/antiviral/index.htm.  
 
Neuraminidase Inhibitor Antiviral Drugs: Small numbers of influenza viruses resistant to 
the neuraminidase inhibitor oseltamivir have been detected in the United States.  Of the 350 
influenza A and B viruses tested for antiviral resistance so far this season, 16 (4.6%) have 
been found to be resistant to oseltamivir.  Currently all of the resistant viruses are H1N1 
viruses, with 16 (8.1%) of all H1N1 viruses exhibiting a genetic mutation that confers 
oseltamivir resistance.  These resistant viruses have been found sporadically across four of 
the nine surveillance regions.  All tested viruses retain their sensitivity to zanamivir.  
Additional information on antiviral resistance can be found at: 
http://www.cdc.gov/flu/about/qa/antiviralresistance.htm 
 
Adamantane Antiviral Drugs: Resistance to the adamantanes continues to be high.  
Among 271 influenza A viruses tested, 87 (32.1%) are resistant to adamantanes, including 
98.6% of H3N2 viruses and 7.6% of H1N1 viruses.  The adamantanes are not effective 
against influenza B viruses.   
 
Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, 
and persisting high levels of resistance to the adamantanes in both H3N2 and H1N1 
viruses, CDC continues to recommend the use of oseltamivir and zanamivir for the 
treatment or prevention of influenza.  Use of amantadine or rimantadine is not 
recommended.  Guidance on influenza antiviral use can be found at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 6, 7.6% of all deaths 
reported through the 122 Cities Mortality Reporting System were reported as due to P&I. This 
percentage is above the epidemic threshold of 7.2% for week 6.  Including week 6, P&I mortality 
has been above threshold for five consecutive weeks. 
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Influenza-Associated Pediatric Mortality: Nine (including the five unofficial notifications reported 
in week 5) influenza-associated pediatric deaths were reported to CDC during week 6 [AK(1), 
MS(2), NY(2), TN(1), and TX(3)].  Since September 30, 2007, CDC has received a total of ten 
reports of influenza-associated pediatric deaths that occurred during the current season.   
Number of Influenza-Associated Pediatric Deaths
by Week of Death:
2005-06 season to present
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Influenza-Associated Pediatric Hospitalizations:  Laboratory-confirmed influenza-associated 
pediatric hospitalizations are monitored in two population-based surveillance networks: the New 
Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
During November 4, 2007-January 26, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the NVSN for children 0-4 years old was 0.73 per 
10,000.   
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2007- 08 and Previous 2 Seasons
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During September 30 – February 2, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the EIP for children 0–17 years old was 0.36 per 10,000.  
For children aged 0-4 years and 5-17 years, the rate was 1.0 per 10,000 and 0.1 per 10,000, 
respectively.  
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children Aged 0-4 and 5-17 yrs, 2007-2008 and 
Previous 2 Seasons
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Outpatient Illness Surveillance:  Nationwide during week 6, 5.7% of outpatient visits reported 
through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness 
(ILI), which is above the national baseline of 2.2%.  On a regional level, the percentage of visits for 
ILI increased in eight of the nine regions compared to last week and ranged from 3.1% to 9.5%. All 
nine regions reported ILI above their region-specific baselines.  
 
Starting in week 5, New York City began reporting ILI data collected electronically from emergency 
departments city-wide, adding approximately 60,000 additional patient visits per week to the U.S. 
Influenza Sentinel Provider Surveillance Network.  Retrospective reports were submitted for all 
earlier weeks this season.  While this change increases the total patient visits per week by 
approximately 15%, it is not expected to influence the national ILI outpatient visit percentage after 
population weighting, but may have a larger impact on the Mid-Atlantic regional ILI percentage. 
 
During week 6, 3.5% of patient visits to Department of Veteran’s Affairs (VA) and Department of 
Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was 
above the national baseline of 3.2%.  On a regional level, the percentage of visits for ARI ranged 
from 1.6% to 4.1%, and was at or above the East North Central, East South Central, Mountain, 
Pacific, West North Central, and West South Central region-specific baselines.  The percentage of 
visits reported for ARI was at or above age-specific baselines in the 5-17 years, 18-49 years, 50-64 
years, and >64 years age groups.   
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Percentage of Visits for ILI & ARI Reported
by Sentinel Providers and BioSense Outpatient Facilities,
National Summary
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Percentage of Visits for ARI by Age Group Reported by 
DoD/VA Outpatient Clinics - National Summary
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: During 
week 6 the following influenza activity was reported: 
• Widespread activity was reported by 44 states (Alabama, Alaska, Arizona, Arkansas, 
California, Colorado, Connecticut, Delaware, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, 
Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North 
Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, 
Tennessee, Texas, Vermont, Virginia, Washington, Wisconsin, West Virginia, and 
Wyoming). 
• Regional activity was reported by 5 states (Maine, Missouri, Oregon, Rhode Island, and 
Utah). 
• Local activity was reported by the District of Columbia and one state (Florida). 
• Sporadic activity was reported by Puerto Rico. 
 
 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: February 15, 2008.
  
   
